Caliway Biopharmaceuticals Co. L (6919) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT
61.9B, trading at NT
04.00 on the TAI. This SniperIQ fundamentals page covers Caliway Biopharmaceuticals Co. L's valuation, profitability (net margin -744.4%), revenue (NT
8M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapNT
61.9B
Net Margin-744.4%
Revenue (FY25)NT
8M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Caliway Biopharmaceuticals Co. L's market cap?
Caliway Biopharmaceuticals Co. L (6919) has a market capitalization of approximately NT
61.9B, trading at NT
04.00 on the TAI. Market cap moves with the live share price.
What is Caliway Biopharmaceuticals Co. L's P/E ratio?
Caliway Biopharmaceuticals Co. L's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 17.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Caliway Biopharmaceuticals Co. L?
Caliway Biopharmaceuticals Co. L runs a net profit margin of -744.4%, a gross margin of -12.2%, and an operating margin of -1908.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Caliway Biopharmaceuticals Co. L generate?
Caliway Biopharmaceuticals Co. L reported revenue of NT
8M for fiscal year 2025, with net income of -NT
51M and earnings per share (EPS) of -0.23. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Caliway Biopharmaceuticals Co. L pay a dividend?
Caliway Biopharmaceuticals Co. L does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Caliway Biopharmaceuticals Co. L financially healthy?
Caliway Biopharmaceuticals Co. L carries a debt-to-equity ratio of 0.00x and a current ratio of 45.21x, with a market beta of 1.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Caliway Biopharmaceuticals Co. L a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Caliway Biopharmaceuticals Co. L (6919) the key facts are: market cap NT
61.9B, revenue NT
8M, 52-week range 75.1-277. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Caliway Biopharmaceuticals Co. L's full fundamentals live
Get Caliway Biopharmaceuticals Co. L's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.